Home Blog Page 10

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Forecasting new product revenues

Go to paper

ABSTRACT: This paper discusses real-life experiences in developing revenue forecasts for biopharmaceutical clients. The importance of forecasts based on emerging information about the product, market conditions and the competitive landscape is emphasised.

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Drug Patent Expirations for October 2013

TradenameApplicantGeneric NamePatent NumberPatent Expiration
OMNISCANGe Healthcaregadodiamide5,560,903Oct 1, 2013
ELOXATINSanofi Aventis Usoxaliplatin5,338,874*PEDOct 7, 2013
LYRICAPf Prismpregabalin5,563,175Oct 8, 2013
RESCRIPTORViiv Hlthcaredelavirdine mesylate5,563,142Oct 8, 2013
RAXAROtsukagrepafloxacin hydrochloride5,563,138Oct 8, 2013
JENLOGAConcordia Pharms Incclonidine hydrochloride5,869,100Oct 13, 2013
KAPVAYConcordia Pharms Incclonidine hydrochloride5,869,100Oct 13, 2013
PROPECIAMerckfinasteride5,547,957Oct 15, 2013
STALEVO 100Orion Pharmacarbidopa; entacapone; levodopa5,446,194Oct 19, 2013
STALEVO 150Orion Pharmacarbidopa; entacapone; levodopa5,446,194Oct 19, 2013
COMTANOrion Pharmaentacapone5,446,194Oct 19, 2013
STALEVO 50Orion Pharmacarbidopa; entacapone; levodopa5,446,194Oct 19, 2013
STALEVO 125Orion Pharmacarbidopa; entacapone; levodopa5,446,194Oct 19, 2013
STALEVO 200Orion Pharmacarbidopa; entacapone; levodopa5,446,194Oct 19, 2013
STALEVO 75Orion Pharmacarbidopa; entacapone; levodopa5,446,194Oct 19, 2013
LOTEMAXPharmosloteprednol etabonate5,540,930Oct 25, 2013
MACUGENValeant Pharms Llcpegaptanib sodium6,113,906Oct 27, 2013
MACUGENValeant Pharms Llcpegaptanib sodium5,919,455Oct 27, 2013
BACTROBANGlaxosmithklinemupirocin calcium5,569,672Oct 29, 2013
YAZBayer Hlthcaredrospirenone; ethinyl estradiol5,569,652Oct 29, 2013
YASMINBayer Hlthcaredrospirenone; ethinyl estradiol5,569,652Oct 29, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

journal-of-commercial-biotechnology_160Made available by the elective open access option at the Journal of Commercial Biotechnology, this paper is free to view without subscription:

Assessing the history and value of Human Genome Sciences
Laura M. McNamee, Fred D Ledley

Abstract

Human Genome Science (HGS) aspired to dominate the emergent field of genomics by discovering expressed gene sequences and developing therapeutic and diagnostic products based on proprietary genes. While HGS’ accomplishments fell short of their own lofty expectations, by the time HGS was acquired by GlaxoSmithKline, the company had extensive intellectual property and had launched a product with >$1 billion market potential. Nevertheless, HGS’ acquisition price was less than the total capital investments in the company. This work examines HGS’ history and accomplishments in the context of the business plan described by the company at their IPO. We focus specifically on the company’s valuation over time, which was highly correlated with general market indices, but negatively correlated with metrics of technical or clinical progress. The history of HGS points to the challenge of accounting for the value created by a science-based business plan. Earnings-based metrics, present value calculations, and “fair value” assessments did not account for HGS’ progress in executing their stated business plan. This work highlights the critical need for accounting practices that credit value to the progress of translational science and enable investors to profit from such investments.

In addition to hosting a comprehensive database of drug and patent-related information, DrugPatentWatch also is also a source for old versions of the FDA Orange Book, or Approved Drug Products with Therapeutic Equivalence Evaluations. More information is available in the Report Store, or you use the direct links below:

1995 Orange Book

1998 Orange Book

1999 Orange Book

2005 Orange Book

2006 Orange Book

2007 Orange Book

2008 Orange Book

2009 Orange Book

2010 Orange Book

2011 Orange Book

2012 Orange Book

On a recent press tour of the Berlin and Saxony region I came across something I wasn’t expecting. Germany has instituted a set of very progressive (or, aggressive) policies to phase out nuclear and carbon-based energy in favor of renewable sources. I saw a lot of interesting wind, solar, and other projects (more on these later), but also saw something I really wasn’t expecting — a large group of Libyan engineers learning about these renewable energy sources and how to integrate them with existing power grids.

libyan windfarmMy immediate question was “why would an oil-rich country like Libya be interested in developing renewable energy?” The answers were illuminating.

“We only have 50 years of oil left” was the first answer. With the Libyan political system currently in turmoil, it is impressive that there are stakeholders looking for sustainable means to promote stability. Much support comes from EU funding to North African nations to supply renewable energy to proximal member states such as Spain and Italy. It is worth noting that the potential for solar, and likely wind energy, in Libya far exceeds the oil resources–Germany has made great investments in solar energy, but they are limited by solar exposure similar to that of Alaska. North African countries have longer photoperiods with less seasonality, and less cloud cover. The large unpopulated areas also mean fewer siting problems (and great opportunities for economic development outside urban areas).

Another rationale presented is that oil resources are currently used to generate electricity in Libya. Finding alternative means to produce electricity can increase the amount of oil that Libya can sell, ultimately improving the country’s wealth. Furthermore, great efforts are necessary to ensure that remote habitations are supplied with electricity. Setting up independent power grids can avoid long, lossy, runs of electricity.

A final rationale is that production of energy from non-oil resources holds the potential to decrease the political power of foreign oil extraction firms.

I will follow up in a future with more on my general observations and thoughts on Germany’s energy policies.

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Distribution of data and unique material resources made with NIH funding

Go to paper

ABSTRACT: The research community, particularly in academic and public sector institutions, recognises that scientists have an obligation to publish the results of their research and otherwise make available data or unique materials that are necessary for others to replicate or advance their research. Over the past 15 years, the US National Institutes of Health (NIH) has developed policies to make such obligations a requirement for recipients of NIH funding...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Commercial biotechnology in Latin America: Current opportunities and challenges

Go to paper

ABSTRACT: The unparalleled growth of commercial biotechnology in the USA and Europe during the past two decades has also been marked by its steady development in Latin America. Brazil, Cuba, Argentina, Chile, Mexico and others have made significant strides in building their research and production capacity in modern biotechnology...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

drugpatentchallengeThis chart shows the companies with the successful drug patent challenges from last year.

The most successful drug patent challengers in 2012 were Mylan Pharms IncLupin PharmsIvax Sub Teva PharmsTeva PharmsPerrigo IsraelTevaWatson Labs Inc FlDr Reddys Labs LtdInnopharma Inc, and Mylan Labs.

 

For more infographics, see the DrugPatentWatch Pharmaceutical Innovation Infographics.

Do you have a response to this infographic? Respond in the comments section below.

Drug Patent Expirations for September 2013

TradenameApplicantGeneric NamePatent NumberPatent Expiration
LUPRON DEPOTAbbvie Endocrine Incleuprolide acetate5,575,987Sep 2, 2013
LUPRON DEPOT-PEDAbbott Endocrineleuprolide acetate5,575,987Sep 2, 2013
LUPRON DEPOTAbbott Endocrineleuprolide acetate5,716,640Sep 2, 2013
LUPRON DEPOTAbbvie Endocrine Incleuprolide acetate5,716,640Sep 2, 2013
LUPRON DEPOT-PEDAbbott Endocrineleuprolide acetate5,716,640Sep 2, 2013
LUPRON DEPOTAbbott Endocrineleuprolide acetate5,575,987Sep 2, 2013
SYMLINAmylin Pharms Llcpramlintide acetate6,608,029Sep 7, 2013
OPANA EREndo Pharmsoxymorphone hydrochloride5,662,933Sep 9, 2013
OPANA EREndo Pharmsoxymorphone hydrochloride5,958,456Sep 9, 2013
MYRBETRIQApgdimirabegron6,699,503Sep 10, 2013
PRELAYSankyotroglitazone6,046,202Sep 15, 2013
CELLCEPTRoche Palomycophenolate mofetil hydrochloride5,543,408Sep 15, 2013
REZULINPfizer Pharmstroglitazone5,602,133Sep 15, 2013
CRINONEWatson Labsprogesterone5,543,150Sep 15, 2013
PRELAYSankyotroglitazone5,602,133Sep 15, 2013
REZULINPfizer Pharmstroglitazone6,046,202Sep 15, 2013
CANCIDASMerckcaspofungin acetate5,792,746*PEDSep 16, 2013
CANCIDASMerckcaspofungin acetate5,378,804*PEDSep 16, 2013
AVODARTGlaxosmithklinedutasteride5,846,976Sep 17, 2013
JALYNGlaxosmithklinedutasteride; tamsulosin hydrochloride5,846,976Sep 17, 2013
DIASTAT ACUDIALValeantdiazepam5,462,740Sep 17, 2013
AVODARTGlaxosmithklinedutasteride5,998,427Sep 17, 2013
JALYNGlaxosmithklinedutasteride; tamsulosin hydrochloride5,998,427Sep 17, 2013
DIASTATValeantdiazepam5,462,740Sep 17, 2013
NIASPANAbbvieniacin6,406,715Sep 20, 2013
ADVICORAbbvielovastatin; niacin6,746,691Sep 20, 2013
SIMCORAbbvieniacin; simvastatin6,676,967Sep 20, 2013
NIASPANAbbvieniacin7,998,506Sep 20, 2013
ADVICORAbbvielovastatin; niacin6,818,229Sep 20, 2013
SIMCORAbbvieniacin; simvastatin6,818,229Sep 20, 2013
NIASPANAbbvieniacin6,746,691Sep 20, 2013
SIMCORAbbvieniacin; simvastatin7,998,506Sep 20, 2013
ADVICORAbbvielovastatin; niacin6,406,715Sep 20, 2013
NIASPAN TITRATION STARTER PACKAbbvieniacin6,129,930Sep 20, 2013
NIASPANAbbvieniacin6,676,967Sep 20, 2013
SIMCORAbbvieniacin; simvastatin6,406,715Sep 20, 2013
ADVICORAbbvielovastatin; niacin7,998,506Sep 20, 2013
NIASPAN TITRATION STARTER PACKAbbvieniacin6,746,691Sep 20, 2013
NIASPANAbbvieniacin7,011,848Sep 20, 2013
ADVICORAbbvielovastatin; niacin6,676,967Sep 20, 2013
SIMCORAbbvieniacin; simvastatin6,746,691Sep 20, 2013
NIASPANAbbvieniacin6,818,229Sep 20, 2013
SIMCORAbbvieniacin; simvastatin7,011,848Sep 20, 2013
ADVICORAbbvielovastatin; niacin6,129,930Sep 20, 2013
NIASPAN TITRATION STARTER PACKAbbvieniacin7,011,848Sep 20, 2013
NIASPANAbbvieniacin6,129,930Sep 20, 2013
SIMCORAbbvieniacin; simvastatin6,129,930Sep 20, 2013
ADVICORAbbvielovastatin; niacin7,011,848Sep 20, 2013
NIASPAN TITRATION STARTER PACKAbbvieniacin6,406,715Sep 20, 2013
ZYFLO CRCornerstone Therapzileuton6,183,778Sep 21, 2013
NOVOLOG MIX 70/30 FLEXPENNovo Nordisk Incinsulin aspart protamine recombinant; insulin aspart recombinant5,834,422Sep 28, 2013
NOVOLOG MIX 50/50Novo Nordisk Incinsulin aspart protamine recombinant; insulin aspart recombinant5,840,680Sep 28, 2013
NOVOLOG MIX 70/30 PENFILLNovo Nordisk Incinsulin aspart protamine recombinant; insulin aspart recombinant5,834,422Sep 28, 2013
NOVOLOG MIX 50/50Novo Nordisk Incinsulin aspart protamine recombinant; insulin aspart recombinant5,834,422Sep 28, 2013
ELIGARDTolmar Therapleuprolide acetate6,395,293Sep 28, 2013
NOVOLOG MIX 70/30 PENFILLNovo Nordisk Incinsulin aspart protamine recombinant; insulin aspart recombinant5,547,930Sep 28, 2013
NOVOLOG MIX 70/30Novo Nordisk Incinsulin aspart protamine recombinant; insulin aspart recombinant5,840,680Sep 28, 2013
NOVOLOG MIX 70/30 FLEXPENNovo Nordisk Incinsulin aspart protamine recombinant; insulin aspart recombinant5,547,930Sep 28, 2013
NOVOLOG MIX 70/30 FLEXPENNovo Nordisk Incinsulin aspart protamine recombinant; insulin aspart recombinant5,840,680Sep 28, 2013
NOVOLOG MIX 50/50Novo Nordisk Incinsulin aspart protamine recombinant; insulin aspart recombinant5,547,930Sep 28, 2013
NOVOLOG MIX 70/30 PENFILLNovo Nordisk Incinsulin aspart protamine recombinant; insulin aspart recombinant5,840,680Sep 28, 2013
NOVOLOG MIX 70/30Novo Nordisk Incinsulin aspart protamine recombinant; insulin aspart recombinant5,547,930Sep 28, 2013
NOVOLOG MIX 70/30Novo Nordisk Incinsulin aspart protamine recombinant; insulin aspart recombinant5,834,422Sep 28, 2013
COMBIVENT RESPIMATBoehringer Ingelheimalbuterol sulfate; ipratropium bromide5,911,851Sep 29, 2013
COMBIVENT RESPIMATBoehringer Ingelheimalbuterol sulfate; ipratropium bromide6,503,362Sep 29, 2013
COMBIVENT RESPIMATBoehringer Ingelheimalbuterol sulfate; ipratropium bromide6,007,676Sep 29, 2013
COMBIVENT RESPIMATBoehringer Ingelheimalbuterol sulfate; ipratropium bromide5,472,143Sep 29, 2013
LIDOSITE TOPICAL SYSTEM KITVyterisepinephrine; lidocaine hydrochloride5,873,850Sep 30, 2013
LEVULANDusaaminolevulinic acid hydrochloride5,079,262Sep 30, 2013
LIDOSITE TOPICAL SYSTEM KITVyterisepinephrine; lidocaine hydrochloride6,385,488Sep 30, 2013
LIDOSITE TOPICAL SYSTEM KITVyterisepinephrine; lidocaine hydrochloride6,377,847Sep 30, 2013
LIDOSITE TOPICAL SYSTEM KITVyterisepinephrine; lidocaine hydrochloride5,246,418Sep 30, 2013
LIDOSITE TOPICAL SYSTEM KITVyterisepinephrine; lidocaine hydrochloride6,862,473Sep 30, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.